ET743-SAR-3007, A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma
The purpose of this study is to compare the effects, good and/or bad of the study drug, trabectedin, with the commonly used drug Dacarbazine to find out which is better.
*Subjects must be 15 years of age or older.
*Subjects must have a diagnosis of either cancer of fat cells or cancer of smooth muscle.
*Have had prior anti-cancer treatment.
*Subject's medical history will be reviewed in detail for study eligibility.
15 - 100
Healthy Volunteers Needed
Duration of Participation
Clinical Trials Information Line: Phone 503-494-1080 or firstname.lastname@example.org
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.